Risk of Cognitive Effects in Comorbid Patients With Prostate Cancer Treated With Androgen Receptor Inhibitors
Open Access
- 18 March 2021
- journal article
- review article
- Published by Elsevier BV in Clinical Genitourinary Cancer
- Vol. 19 (5), 467.e1-467.e11
- https://doi.org/10.1016/j.clgc.2021.03.014
Abstract
No abstract availableFunding Information
- Genentech
- Pfizer
- Sanofi
- Astellas Pharma US
- Janssen Pharmaceuticals
- Amgen
- Bayer Fund
- Bristol-Myers Squibb
- Bayer HealthCare
- AstraZeneca
This publication has 100 references indexed in Scilit:
- Increased Survival with Enzalutamide in Prostate Cancer after ChemotherapyThe New England Journal of Medicine, 2012
- Effects of androgen deprivation on brain function in prostate cancer patients – a prospective observational cohort analysisBMC Cancer, 2012
- Prostate cancer treatments and their side effects are associated with increased insomniaPsycho‐Oncology, 2012
- Use of CNS medications and cognitive decline in the aged: a longitudinal population-based studyBMC Geriatrics, 2011
- Testosterone levels and cognition in elderly men: A reviewMaturitas, 2011
- Neuroanatomical substrates of age-related cognitive decline.Psychological Bulletin, 2011
- Cognitive impairment in men with testicular cancer prior to adjuvant therapyCancer, 2010
- Confronting chemobrain: an in-depth look at survivors’ reports of impact on work, social networks, and health care responseJournal of Cancer Survivorship, 2009
- Androgens modulate β‐amyloid levels in male rat brainJournal of Neurochemistry, 2003
- Immunocytochemical detection of androgen receptor in human temporal cortex: Characterization and application of polyclonal androgen receptor antibodies in frozen and paraffin-embedded tissuesThe Journal of Steroid Biochemistry and Molecular Biology, 1995